The importance and challenge of comparing stroke care, utilization and outcomes in Medicare Advantage and Fee-for-Service Medicare: a narrative review and vision for the future [0.03%]
比较医疗保险优势和按服务收费的医疗保险中的卒中护理、利用情况和结果的重要性与挑战：叙述性回顾及未来展望
Emily J Bian,Priyanka Menon,Kathleen A McManus et al.
Emily J Bian et al.
Stroke prevalence is highest in adults ≥65 years, the majority of whom are Medicare beneficiaries. Fee-for-Service Medicare (FFS) incentivizes utilization by paying for each service. Medicare Advantage (MA) uses capitated payments to reduc...
Difference in hospital readmission among patients with atrial fibrillation undergoing ablation using nonintegrated pulsed field catheter with CARTO™ 3 versus EnSite™ electroanatomical mapping system [0.03%]
采用Carto™ 3系统与Ensite™电生理标测系统行非一体化脉冲导管消融治疗房颤患者的再住院差异分析研究
Alexandru I Costea,Rahul Khanna,Maximiliano Iglesias et al.
Alexandru I Costea et al.
Aim: Pulsed field ablation (PFA) is a minimally thermal alternative to traditional thermal catheter ablation for atrial fibrillation (AF), with comparable efficacy and minimal risk of collateral tissue injury. Three-dimensional (3D) electro...
Access in all areas? A round-up of developments in market access and health technology assessment: part 12 [0.03%]
处处有径通罗马？市场准入和卫生技术评估的最新动态（一）
Sreeram V Ramagopalan,Annie Jullien Pannelay
Sreeram V Ramagopalan
In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy. ...
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer [0.03%]
基于人口调整的网状meta分析为转移性雄激素敏感型前列腺癌治疗方案的有效性提供了新的见解
Neal Shore,Alicia K Morgans,Noman Paracha et al.
Neal Shore et al.
Aim: Recent network meta-analyses (NMAs) in metastatic castration-sensitive prostate cancer have not adequately addressed potential treatment effect modifiers and population imbalances, which introduces bias. Although, individual-patient da...
Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease [0.03%]
用于评估两种固定剂量三联疗法在中至极重度慢性阻塞性肺疾病患者中降低死亡风险的成本效益分析模型
Krishnali Parsekar,Shubhram Pandey,Deniz Tansey-Dwyer et al.
Krishnali Parsekar et al.
Aim: Two fixed-dose combination triple therapies, budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 μg and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg, have been shown to reduce all-caus...
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison [0.03%]
洛拉替尼与艾乐昔替尼治疗ROS1阳性晚期/转移性非小细胞肺癌的长期疗效和安全性：匹配调整后的间接比较分析
Todd Bauer,Devin Abrahami,Anna Polli et al.
Todd Bauer et al.
Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data fro...
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 23 [0.03%]
一石二鸟：真实世界证据在支付与准入中的应用综述第二部分
Paul Arora,Sreeram V Ramagopalan
Paul Arora
In this update, we explore a review on transportability methods to enable the use of cross-jurisdictional evidence when local data are limited, a review of clinical trials that use pragmatic elements and finally, we discuss a study highligh...
Acceptability of external control-arm use in nononcology health technology assessment submissions [0.03%]
外部对照在非肿瘤健康技术评估中的应用接受度分析
Kamal Kant Mangla,Spyros Kolovos,Ana Lisica et al.
Kamal Kant Mangla et al.
Aim: This study assessed the acceptability of external control-arm (ECA) use in nononcology health technology assessment (HTA) submissions in Europe. Materials & methods: We conducted a sequential mixed method study to investigate the study...
Healthcare cost and utilization before and after the development of significant tricuspid regurgitation by age, sex and race [0.03%]
不同年龄、性别和种族的显著三尖瓣反流发生前后的医疗费用和利用率分析
David P Cork,Frank Medina,Lisa Kemp et al.
David P Cork et al.
Background: The impact of significant tricuspid regurgitation (sTR) on healthcare costs and utilization in real-world populations remains understudied. Aim: Describe healthcare costs and utilization before and after development of sTR and d...
Racial and ethnic differences in diagnosis, healthcare utilization and 1-year outcomes for patients with significant tricuspid regurgitation [0.03%]
种族和民族在三尖瓣反流患者诊断、医疗使用及一年预后方面的差异
Frank Medina,David P Cork,Rebecca Horn et al.
Frank Medina et al.
Background: The impact of race and ethnicity on prognosis and clinical outcomes in patients with significant tricuspid regurgitation (sTR) is not well understood. Aim: Describe healthcare utilization trends preceding the development of sTR ...